Inflammation and Fibrosis: Two Processes, Different Consequences

Inflammation and fibrosis are closely related processes, but they are not interchangeable.

Inflammation is part of the immune response to injury or other biological threats. When inflammation persists or becomes dysregulated, it can contribute to ongoing tissue damage. Fibrosis involves the accumulation and remodeling of connective tissue, which can alter normal tissue structure and function.

Both processes are relevant to chronic graft-versus-host disease, including ocular GVHD.

Within the eye, inflammation may affect the conjunctiva, lacrimal glands, eyelids, and other components of the ocular surface. Chronic tissue injury and remodeling can contribute to scarring and loss of normal function.

The distinction matters because reducing inflammatory activity and restoring tissue that has already undergone structural change are different scientific challenges.

A reduction in inflammation does not necessarily mean that established fibrosis has resolved. Likewise, protecting a damaged ocular surface does not, by itself, demonstrate that the underlying immune process has been controlled.

For researchers, this distinction raises important questions about disease stage, treatment targets, and outcome measurement. Which changes reflect active inflammation? Which indicate longer-term structural damage? Can clinical assessments or biomarkers distinguish between these processes?

These questions matter when interpreting treatment response. Different biological processes may change at different rates, and one measurement may not capture every aspect of disease activity.

Understanding inflammation and fibrosis as related but distinct processes can help clarify the complexity of oGVHD and the scientific questions involved in developing more effective approaches to care.

This article is for educational purposes only and is not medical advice.

Sources: 

  1. Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/
  2. Tappeiner C, Heiligenhaus A, Halter JP, et al. Frontiers in Medicine, 2023. https://doi.org/10.3389/fmed.2023.1133381

Join Our Mission

Signal12 is planning to facilitate Phase 3 clinical trials in 2026 and bring Pro-ocular™ to market.

Contact Us Today